Brief: Alvotech And Teva Announce U.S. Approval Of Simlandi Injection
24/02/2024 01:17
Feb 23 (Reuters) - Alvotech SA ALVO.O :
* REG-ALVOTECH AND TEVA ANNOUNCE U.S. APPROVAL OF SIMLANDI®
(ADALIMUMAB-RYVK) INJECTION, THE FIRST INTERCHANGEABLE
HIGH-CONCENTRATION, CITRATE-FREE BIOSIMILAR TO HUMIRA®
* SIMLANDI WILL QUALIFY FOR INTERCHANGEABLE EXCLUSIVITY IN
U.S.
FOR SOME CONCENTRATION STRENGTHS
* BOTH ALVOTECH AND TEVA EXPECT TO LAUNCH SIMLANDI IN U.S.
IMMINENTLY WITH INTERCHANGEABILITY DESIGNATION.
* SIMLANDI CAN BE SUBSTITUTED FOR HUMIRA AT PHARMACY LEVEL,
SUBJECT TO STATE PHARMACY LAWS.
Source text for Eikon: ID:nGNEsZLMR
Further company coverage: ALVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm